Insights On Trial Design
-
The Benefits Of Blinding of Investigational Medicinal Products (IMPs)
6/26/2018
How blinding benefits both the patient and the investigator and drug encapsulation is an effective blinding method.
-
Six Trends Shaping Tomorrow's Clinical Trials
7/2/2018
Due to the continuous growth in drug development costs, there has never been a greater need for new and innovative ways to support the clinical trial supply chain. Explore key trends that are pushing the innovation envelope.
-
Maximizing Success In Early Stage Oncology Trials: Considerations And Strategies In The Era Of Molecularly Targeted Agents
12/26/2018
Making a meaningful impact on the survival and quality of life of patients with cancer remains a significant challenge. This white paper discusses considerations and strategies for maximizing the likelihood of success in early phase oncology trials and developing significantly improved therapeutics for patients.
-
Plain-Language Summaries Best Practices
4/16/2019
Today’s healthcare industry is hyper-focused on patient engagement. With plain-language summaries (PLS), clinical trial sponsors can make patient engagement more than a mantra. In this video, learn PLS best practices from two expert authorities.
-
Successful BYOD In Any Phase
3/6/2020
The idea of BYOD for use in clinical trials during any phase has historically been conceptualized as a futuristic alternative, rather than what it actually is — a viable option for many clinical trials. While there has typically been hesitance among sponsors and CROs to choose a BYOD model for their study, there is an increasing number of trials that have successfully deployed this model with great results. Read more about the Advantages and Misconceptions of BYOD and what you should consider if you are deciding whether BYOD is an option for your study.
-
How Ramping Up Communications Helped Overcome A Next-To-Impossible Recruitment Challenge
4/21/2020
We knew going in that it could be the perfect recruiting nightmare with extremely complex inclusion/exclusion criteria. By letting sites set their own goals and commit to them along with assigning project coordinators that stayed close to those sites the study is off to a good start.
-
Basket Clinical Trial Designs: The Key To Testing Innovative Therapies Is Innovation In Study Design And Conduct
3/4/2020
As the science behind therapeutic interventions has deepened and grown, the clinical trial designs through which those interventions can be best tested have evolved as well. To study therapies directed against specific abnormalities, in cancer for example, it may make sense to include anyone with the target abnormality in the trial population, regardless of the location of their cancer.
-
Age Diversity In Clinical Trials: Addressing The Unmet Need
7/10/2018
In a recent New York Times article, Paula Span raises the concern that elderly subjects are frequently omitted from clinical trials. Consequently, physicians know very little about how a given treatment may affect their older patients. Is a medication effective for the elderly? Is it safe? Without data, how is a physician to know?
-
Adaptive Trial Design and Implementation
10/31/2018
Understand the concept and benefits of adaptive trials and if they should be a consideration for your company.
-
Ensuring An Unbiased Comparator Arm In Clinical Development
2/26/2020
Regulators in the U.S. and Europe have issued a positive response to the use of synthetic control arms (SCAs) in clinical development. The desire for faster and less expensive clinical trials, coupled with the availability of real-world data, were prominent factors. Learn how to avoid sampling bias when using real-world data in conjunction with SCAs.